The DDS Program at Touro Dental School in New York

A dentist anesthesiologist at a New York City hospital and the owner of a mobile anesthesiology practice, Dr. Raquel Rozdolski has been in her field since 2012. Dr. Raquel Rozdolski is an assistant clinical professor at Touro College of Dental Medicine in Hawthorne, New York.

Admitting its first students in 2016, Touro responded to a rapidly changing profession by using state-of-the-art technology in its four-year DDS program. The curriculum comprises two parts: preclinical study and clinical practice.

The first program moves beyond the knowledge of the teeth to encompass the entire body, with coursework in anatomy, physiology, biochemistry, and other disciplines. Students learn in an immersive virtual laboratory that simulates actual procedures. By helping them adopt a scientist’s perspective, teachers prepare them for implants, CT scanning, and other aspects of modern dentistry. Participants also examine questions of ethics and practice management.

Students then proceed to the two-year clinical practice track. They learn teamwork and accountability under several full- and part-time faculty supervision. As students build experience, they blend theory with practice in seminars. For further information on Touro’s DDS program, please visit dental.touro.edu.

New York’s Touro College of Dental Medicine

Dentist anesthesiologist Dr. Raquel Rozdolski owns Sweet Dreams Dental Anesthesia, which provides mobile sedation services for children and adults. In addition, Dr. Raquel Rozdolski teaches at the Touro College of Dental Medicine in Hawthorne, New York.

Being a new institution (classes began in 2016), Touro offers a four-year DDS program that features state of the art dental technology and hands-on experience in a fully equipped clinic. It also sponsors the Pre-Dental Experience for students wishing to learn more about the profession.

The DDS curriculum covers the complete spectrum of best practices. In the first year, students learn physiology, biochemistry, radiology, ethics, and other topics. Second-year participants discover how to manage pain and deal with patients’ anxiety, in addition to medical issues. In the third year, they begin clinical training, learn about practice management, and spend time with pediatric patients. In year four, they delve into concepts such as patient management and the hospital environment, as well as learning the relationships between various branches of dentistry. For more information, please visit dental.touro.edu.

How Boston Anesthesiologists Are Making the Most Effective Drugs Safe

Dr. Raquel Rozdolski is a board-certified Dentist Anesthesiologist and owner of Sweet Dreams Dental Anesthesia, PLLC where she provides care to children and adults, with a focus on patients with intellectual and developmental disabilities. In her work, Dr. Rozdolski is an advocate of managing pain via non-opioid based approaches. One way to eliminate the need for post-operative opioids is with a localized injection of a slow-release local anesthetic, such as liposomal bupivicaine.

Liposomal bupivicaine (Exparel) provides long-acting, localized, non-opioid based pain control after dental procedures. This method of pain control works directly at the surgical site, rather than taking an opioid which affects the entire body. Liposomal bupivicaine provides pain control for the first couple of days after surgery by slowly releasing local anesthesia particles from the liposomes, thereby eliminating the need for opioids. Liposomal bupivicaine is often supplemented with other non-opioid based pain management medications such as Acetaminophen and Ibuprofen.

“Novel Medications for Dental Anesthesia Practice in the Year 2020”

As a board-certified dentist anesthesiologist, Dr. Raquel Rozdolski owns and operates Sweet Dreams Dental Anesthesia in New York. To inform her professional activities, Dr. Raquel Rozdolski holds active membership in a number of organizations, including the American Society of Dentist Anesthesiologists (ASDA).

As part of its commitment to promoting safe and effective dental anesthesiology, the ASDA educates its members and other health professionals through on-demand webinars such as “Novel Medications for Dental Anesthesia Practice in the Year 2020.” Although roughly a year old, this recorded session remains a viable resource on recent dental anesthesia medications.

Presented by Sean M. Thoms, DMD, MS, the session presents information about the pain management drugs sublingual sufentani (brand name Dsuvia) and liposomal bupivacaine (brand name Exparel). Dr. Thoms praises the shorter half-life of the new sedative remimzolam (Byfavo) as a pathway to safer moderate dental sedation. He also discusses the systolic blood pressure medication clevidipine (Cleviprex) and the anti-nausea medication netupitant/palonosetron (Akynzeo).